IPP Bureau
Max Healthcare collaborates with Lakshdeep Group for revival and turnaround of Jaypee Healthcare
By IPP Bureau - September 14, 2024
The acquisition is based on an enterprise value of Rs. 1,660 crore
DFC commits US $20 mn loan to Panacea Biotec towards capacity expansion for hexavalent vaccine
By IPP Bureau - September 13, 2024
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Strides secures shareholders approval for OneSource CDMO
By IPP Bureau - September 12, 2024
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
Briefs: Medicamen Biotech, Aurobindo Pharma and Ajooni Biotech
By IPP Bureau - September 12, 2024
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
India approves health insurance cover of Rs 5 lakh for all aged 70 years and above
By IPP Bureau - September 12, 2024
This aims to benefit approximately 4.5 crore families with six crore senior citizens with Rs. 5 lakh free health insurance cover on a family basis
Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
By IPP Bureau - September 12, 2024
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Merck launches single-use reactor to accelerate ADC manufacturing
By IPP Bureau - September 12, 2024
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
AGC and Medinet sign agreement for cell therapy CDMO business
By IPP Bureau - September 12, 2024
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington
By IPP Bureau - September 11, 2024
Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding
Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast
By IPP Bureau - September 11, 2024
ALS patients experience neuroinflammation and rapid neurodegeneration
Evonik starts operation of new spray drying facility for pharmaceutical oral excipients
By IPP Bureau - September 11, 2024
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
NHA and IIT Kanpur sign MoU for development of digital public goods for AI in healthcare
By IPP Bureau - September 11, 2024
The partnership aims to revolutionize Artificial Intelligence in health research with innovative data platform
Pfizer highlights diverse oncology portfolio and combination approaches at ESMO 2024
By IPP Bureau - September 11, 2024
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
Merck announces positive top-line results from Phase 3 trial evaluating efficacy and safety of Gardsil 9
By IPP Bureau - September 11, 2024
The trial met its primary and secondary endpoints demonstrating that administration of a 3-dose regimen of GARDASIL 9
Health Ministry releases "Health Dynamics of India (Infrastructure and Human Resources) 2022-23"
By IPP Bureau - September 10, 2024
The publication serves as a foundational tool for identifying gaps and addressing needs in various areas, including rural, urban, and tribal regions
